- Home
- HSCS vs KPRX Comparison
HSCS vs KPRX Comparison
Compare HSCS & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- KPRX
- Stock Information
- Founded
- HSCS 2007
- KPRX 1998
- Country
- HSCS United States
- KPRX United States
- Employees
- HSCS N/A
- KPRX N/A
- Industry
- HSCS Medical Specialities
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HSCS Health Care
- KPRX Health Care
- Exchange
- HSCS Nasdaq
- KPRX Nasdaq
- Market Cap
- HSCS 9.9M
- KPRX 9.2M
- IPO Year
- HSCS 2022
- KPRX N/A
- Fundamental
- Price
- HSCS $3.16
- KPRX $2.46
- Analyst Decision
- HSCS Strong Buy
- KPRX Strong Buy
- Analyst Count
- HSCS 2
- KPRX 1
- Target Price
- HSCS $10.50
- KPRX $10.00
- AVG Volume (30 Days)
- HSCS 25.5K
- KPRX 49.9K
- Earning Date
- HSCS 12-15-2025
- KPRX 11-07-2025
- Dividend Yield
- HSCS N/A
- KPRX N/A
- EPS Growth
- HSCS N/A
- KPRX N/A
- EPS
- HSCS N/A
- KPRX N/A
- Revenue
- HSCS $6,250.00
- KPRX N/A
- Revenue This Year
- HSCS N/A
- KPRX N/A
- Revenue Next Year
- HSCS N/A
- KPRX N/A
- P/E Ratio
- HSCS N/A
- KPRX N/A
- Revenue Growth
- HSCS N/A
- KPRX N/A
- 52 Week Low
- HSCS $2.52
- KPRX $2.21
- 52 Week High
- HSCS $6.47
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- HSCS 36.80
- KPRX 40.93
- Support Level
- HSCS $3.16
- KPRX $2.21
- Resistance Level
- HSCS $3.43
- KPRX $2.68
- Average True Range (ATR)
- HSCS 0.16
- KPRX 0.15
- MACD
- HSCS -0.04
- KPRX -0.02
- Stochastic Oscillator
- HSCS 1.67
- KPRX 38.28
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.